![](/images/graphics-bg.png)
The Prevention of Postmenopausal Osteoporotic Fractures : Results of the Health Technology Assessment of a New Antiosteoporotic Drug
Joint Authors
Kheiraoui, Flavia
de Waure, Chiara
La Torre, Giuseppe
Nicolotti, Nicola
Ricciardi, Gualtiero
Capizzi, Silvio
Veneziano, Maria Assunta
Gualano, Maria Rosaria
Sferrazza, Antonella
Capri, Stefano
Cadeddu, Chiara
Di Pietro, Maria Luisa
Specchia, Maria Lucia
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-04
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
Objective.
The Health Technology Assessment (HTA) approach was applied to denosumab in the prevention of osteoporotic fractures in postmenopausal women.
Method.
Epidemiological, clinical, technical, economic, organizational, and ethical aspects were considered.
Medical electronic databases were accessed to evaluate osteoporosis epidemiology and therapeutical approaches.
A budget impact and a cost-effectiveness analyses were performed to assess economic implications.
Clinical benefits and patient needs were considered with respect to organizational and ethical evaluation.
Results.
In Italy around four millions women are affected by osteoporosis and have a higher risk for fractures with 70,000 women being hospitalized every year.
Bisphosphonates and strontium ranelate are recommended as first line treatment for the prevention of osteoporotic fractures.
Denosumab is effective in reducing vertebral, nonvertebral, and hip/femoral fractures with an advantage of being administered subcutaneously every six months.
The budget impact analysis estimated a reduction in costs for the National Health Service with the introduction of denosumab.
Furthermore, the economic analysis demonstrated that denosumab is cost-effective in comparison to oral bisphosphonates and strontium ranelate.
Denosumab can be administered in outpatients by involving General Practitioners in the management.
Ethical evaluation is positive because of its efficacy and compliance.
Conclusion.
Denosumab could add value in the prevention of osteoporotic fractures.
American Psychological Association (APA)
de Waure, Chiara& Specchia, Maria Lucia& Cadeddu, Chiara& Capizzi, Silvio& Capri, Stefano& Di Pietro, Maria Luisa…[et al.]. 2014. The Prevention of Postmenopausal Osteoporotic Fractures : Results of the Health Technology Assessment of a New Antiosteoporotic Drug. BioMed Research International،Vol. 2014, no. 2014, pp.1-16.
https://search.emarefa.net/detail/BIM-512888
Modern Language Association (MLA)
de Waure, Chiara…[et al.]. The Prevention of Postmenopausal Osteoporotic Fractures : Results of the Health Technology Assessment of a New Antiosteoporotic Drug. BioMed Research International No. 2014 (2014), pp.1-16.
https://search.emarefa.net/detail/BIM-512888
American Medical Association (AMA)
de Waure, Chiara& Specchia, Maria Lucia& Cadeddu, Chiara& Capizzi, Silvio& Capri, Stefano& Di Pietro, Maria Luisa…[et al.]. The Prevention of Postmenopausal Osteoporotic Fractures : Results of the Health Technology Assessment of a New Antiosteoporotic Drug. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-16.
https://search.emarefa.net/detail/BIM-512888
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-512888